Calcipotriol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Calcipotriol: From Psoriasis to Seborrheic Keratosis
One-Sentence Summary
Calcipotriol is a synthetic vitamin D3 analogue approved internationally for the treatment of plaque psoriasis, acting through the Vitamin D Receptor (VDR) to regulate keratinocyte differentiation and inhibit inflammatory signalling. The TxGNN model predicts it may be effective for Seborrheic Keratosis, but there are currently no clinical trials and no publications directly supporting this specific direction. This prediction is at the model-only stage and requires substantial mechanistic and clinical validation before further exploration is warranted.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plaque psoriasis |
| Predicted New Indication | Seborrheic Keratosis |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Calcipotriol is a synthetic analogue of calcitriol (active vitamin D3) that binds to the Vitamin D Receptor (VDR), a nuclear receptor expressed on keratinocytes and immune cells. VDR activation inhibits keratinocyte hyperproliferation, promotes cellular differentiation, and suppresses pro-inflammatory cytokines (notably IL-17 and IL-23) — all of which underpin its effectiveness in psoriasis therapy.
Seborrheic keratosis (SK) is a common benign epidermal overgrowth characterised by keratinocyte hyperproliferation, frequently driven by activating somatic mutations in FGFR3 and PIK3CA signalling pathways. At a superficial level, a rationale exists: Calcipotriol inhibits keratinocyte proliferation, and SK involves keratinocyte overproduction. However, this reasoning does not hold under scrutiny.
SK is a genetically driven benign neoplasm — its proliferative driver is not inflammatory hyperproliferation (as in psoriasis) but rather oncogenic signalling through the FGFR3/PIK3CA axis, which VDR activation does not directly antagonise. Furthermore, SK carries negligible malignant transformation risk, so the unmet clinical need for a therapeutic agent is minimal. The high TxGNN prediction score most likely reflects the model generalising across “keratinising skin disorders” rather than detecting a disease-specific mechanistic link. Without published literature or clinical trial data, this prediction cannot be advanced beyond a hypothesis-generating finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Calcipotriol is currently not marketed in India. No drug licences have been issued by CDSCO for this compound as of the data cut-off date (2026-04-10).
Safety Considerations
Drug Interactions: The DDinter database has flagged 84 potential drug interactions for Calcipotriol. All interactions are currently classified as Unknown severity, which limits their direct clinical utility for risk stratification. Flagged drug classes include:
- Corticosteroids: Prednisone, Prednisolone, Hydrocortisone, Triamcinolone
- Proton pump inhibitors: Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole
- Antibiotics: Doxycycline, Clarithromycin, Vancomycin
- Antidiabetics: Metformin, Rosiglitazone, Glyburide
- Others: Aspirin, Simvastatin, Sulfasalazine, Morphine, Bupropion, Clotrimazole
Please refer to the package insert for complete warnings and contraindications, as those data are currently unavailable in this Evidence Pack.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a very high TxGNN prediction score (99.96%), this score reflects model generalisation across keratinocyte-related skin disorders rather than a disease-specific mechanistic connection. Seborrheic keratosis is driven by FGFR3/PIK3CA mutation, not by the VDR-regulated inflammatory pathways Calcipotriol modulates; the unmet clinical need is also minimal given SK’s benign and non-malignant nature. With zero supporting clinical trials and zero relevant publications, there is no evidence base to justify further investment.
To proceed, the following is needed:
- Mechanistic validation: In vitro studies using SK-derived keratinocyte models (FGFR3/PIK3CA-mutant cell lines) to determine whether VDR activation has any measurable impact on SK-type proliferative signalling
- Epidemiological signal: Any observational evidence that long-term Calcipotriol users show altered SK incidence or lesion regression
- Clinical need assessment: A formal determination of whether a therapeutic gap exists for SK, given its benign course and low treatment priority
- MOA data retrieval: Query DrugBank API to obtain the complete pharmacological profile of Calcipotriol (Data Gap DG002)
- Safety profile completion: Retrieve CDSCO prescribing information to assess warnings and contraindications (Data Gap DG001)
- Consider reprioritising: Among the top 10 predicted indications, Vulvitis (rank 4) and Vulvar Neoplasm (rank 5) have published literature support (PMID 22968059 and 30785593 respectively) and stronger mechanistic rationale as psoriasis-extension and EMPD chemosensitisation targets — these may be higher-yield candidates for a full evidence deep-dive
⚠️ Disclaimer: This report is for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.